1,246 results on '"Koschmieder, Steffen"'
Search Results
152. Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
153. The Unfolded Protein Response Mediates Resistance in AML and Its Therapeutic Targeting Enhances TKI Induced Cell Death in FLT3-ITD + AML
154. Second Versus First Wave of COVID-19 in Patients with MPN
155. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes
156. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia
157. Establishment of a Genetic System to Coordinate Feeder Cell Growth in Cocultures with Primary Cells
158. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
159. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia
160. Pim2 cooperates with PML-RARα to induce acute myeloid leukemia in a bone marrow transplantation model
161. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells
162. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
163. The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
164. Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
165. CRISPR/Cas9 mediated CXCL4 knockout in human iPS cells of polycythemia vera patient with JAK2 V617F mutation
166. Human DC3 Antigen Presenting Dendritic Cells From Induced Pluripotent Stem Cells
167. CALR frameshift mutations in MPN patient-derived iPS cells accelerate maturation of megakaryocytes
168. Leitlinie - Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen
169. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD-10 D47.1
170. JAK2-V617F and interferon-�� induce megakaryocyte-biased stem cells characterized by decreased long-term functionality
171. Long-term follow-up of recovered MPN patients with COVID-19
172. Models to Study Chronic Myeloid Leukemia Cancer Stem Cells
173. The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
174. Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO)
175. JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality
176. Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis
177. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
178. Myeloproliferative Neoplasien (MPN) – Update 2020
179. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience
180. Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms
181. Flt3-dependent transformation by inactivating c-Cbl mutations in AML
182. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia
183. Role of Transcription Factors C/EBPα and PU.1 in Normal Hematopoiesis and Leukemia
184. A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
185. Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients
186. TNF-α controls Lipocalin-2 expression in PC-3 prostate cancer cells
187. Myeloproliferative Neoplasien (MPN)
188. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
189. Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34+ cell expansion and maturation
190. Ruxolitinib for Myelofibrosis
191. The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth
192. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkittʼs and primary mediastinal large B-cell lymphoma
193. Inflammatory Responses of Astrocytes Are Independent from Lipocalin 2
194. Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches
195. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
196. Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita
197. Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles
198. Dexamethasone nanomedicines for COVID-19
199. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
200. Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.